In this video, I discuss how MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF. 🔥

MindMed has had a impressive run up in 2020. The MMED stock is up nearly 1,130% and what we all wonder is : Could MindMed Stock keep on rising? With a larger psychedelic pipeline than Compass Pathways (CMPS), MindMed has made huge advancements in 2020, one of which is its LSD Neutralizer Technology To Shorten and Stop LSD Trips, which is groundbreaking news for all players in the psychedelic medicines industry.

MindMed has a handful of exciting programs in the works, some of which have important milestones coming up this year. Project Lucy is one of these programs, using therapeutic doses of LSD to treat anxiety disorders. If this gets the go-ahead from regulators, it will proceed with a clinical trial investigating LSD for anxiety disorders. If that happens, the mindmed stock could get a big boost. Another boost could be MindMed’s potential uplisiting on to the Nasdaq.

Currently, the MindMed Stock trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ.

Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMedStock #MindMed #MMED #MMEDF

Similar Posts

The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]

The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]

Listen, Videos

Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.

P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html

Time Stamps
0:00​ – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor

Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​ #MindmedStock​​ #PsychedelicStocks

Interview with Matt Zemon, Co-Founder, Psychable

Interview with Matt Zemon, Co-Founder, Psychable

Listen, Podcasts

In our conversation with Matt, we tackle a variety of extremely important and highly-relevant subject matters such as how technology can be utilized to enhance the community of psychedelic healing, conscious capitalism, corporate responsibility, and how companies like Psychable are willing to go out of their way to connect with investors who are motivated not only by profit, but a company’s ability to contribute to the greater good of humanity.

The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

Listen, Videos

The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.

I had a blast in this interview, and I know you will find it fascinating! Enjoy!

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).

#BrightMinds #PsychedelicStocks #Psilocybin

Meet Bright Minds: The NEXT GEN Psychedelics Company Tackling Pain, Depression and MORE (DRUG/BMBIF)

Meet Bright Minds: The NEXT GEN Psychedelics Company Tackling Pain, Depression and MORE (DRUG/BMBIF)

Listen, Videos

In today’s episode of the Psychedelic Spotlight Podcast, James Hallifax from the Psychedelic Investor YouTube Channel interviews Ian McDonald, CEO of Bright Minds BioScience. For any investors out there, Bright Minds ticker symbol is DRUG on the Canadian CSE and BMBIF on the American OTC market.

In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. Bright Minds is a company working on second and third generation psychedelics to treat a variety of ailments including depression, PTSD, epilepsy, addiction and more. The driving philosophy is that while classic psychedelics such as psilocybin and LSD do show great potential to be used in a therapy setting to treat mental health issues, the compounds also have limitations.

At Bright Minds, the goal is to engineer completely new compounds, often based on the structure of classical psychedelics, that keep the benefits of said drugs while doing away with potential negatives. Important to note is that while psychedelic derived drugs are a focus of the company, they also are creating non-psychedelic compounds for a variety of ailments, including different forms of addiction.

In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
I had a blast in this interview, and I know you will find it fascinating! Enjoy!

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).

#BrightMinds #ThePsychedelicInvestor #PsychedelicStocks